Brokerages expect that Galapagos NV (NASDAQ:GLPG) will post $26.5 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Galapagos NV’s earnings, with estimates ranging from $14.8 million to $38.2 million. Galapagos NV reported sales of $32.38 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 18.2%. The company is expected to announce its next earnings report on Friday, August 4th.
According to Zacks, analysts expect that Galapagos NV will report full-year sales of $26.5 million for the current financial year, with estimates ranging from $87.03 million to $186.41 million. For the next year, analysts forecast that the company will post sales of $224.52 million per share, with estimates ranging from $86.87 million to $406.05 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Galapagos NV.
GLPG has been the subject of several recent analyst reports. Zacks Investment Research upgraded Galapagos NV from a “hold” rating to a “buy” rating and set a $90.00 price target for the company in a report on Wednesday, March 22nd. TheStreet upgraded Galapagos NV from a “d+” rating to a “c” rating in a report on Wednesday. Stifel Nicolaus lifted their price target on Galapagos NV from $65.00 to $83.00 and gave the company a “hold” rating in a report on Monday, May 1st. Janney Montgomery Scott cut Galapagos NV from a “buy” rating to a “sell” rating in a report on Monday, April 24th. Finally, Instinet initiated coverage on Galapagos NV in a report on Wednesday, March 1st. They issued a “buy” rating and a $87.00 price target for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. Galapagos NV has a consensus rating of “Hold” and an average price target of $74.40.
TRADEMARK VIOLATION WARNING: “$26.5 Million in Sales Expected for Galapagos NV (GLPG) This Quarter” was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.chaffeybreeze.com/2017/05/20/26-5-million-in-sales-expected-for-galapagos-nv-glpg-this-quarter.html.
Galapagos NV (NASDAQ:GLPG) traded up 0.22% on Wednesday, reaching $85.38. 195,821 shares of the company’s stock were exchanged. Galapagos NV has a 1-year low of $49.43 and a 1-year high of $94.88. The company has a market capitalization of $3.95 billion, a PE ratio of 853.80 and a beta of 1.85. The company has a 50 day moving average price of $87.50 and a 200-day moving average price of $72.21.
Institutional investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC purchased a new position in Galapagos NV during the fourth quarter valued at $20,631,000. Baker BROS. Advisors LP purchased a new position in Galapagos NV during the third quarter valued at $16,805,000. Renaissance Technologies LLC raised its position in Galapagos NV by 51.4% in the first quarter. Renaissance Technologies LLC now owns 311,200 shares of the biotechnology company’s stock valued at $26,822,000 after buying an additional 105,700 shares in the last quarter. EcoR1 Capital LLC raised its position in Galapagos NV by 12.1% in the fourth quarter. EcoR1 Capital LLC now owns 561,341 shares of the biotechnology company’s stock valued at $36,032,000 after buying an additional 60,765 shares in the last quarter. Finally, Clough Capital Partners L P raised its position in Galapagos NV by 336.1% in the first quarter. Clough Capital Partners L P now owns 74,870 shares of the biotechnology company’s stock valued at $6,453,000 after buying an additional 57,700 shares in the last quarter. 21.08% of the stock is currently owned by institutional investors and hedge funds.
About Galapagos NV
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.